Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
A$ 0
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very poor margins and returns
Data is available to registered users only
Data is available to registered users only
About
Hexima Limited, a biotechnology company, engages in the research and development of plant-derived proteins and peptides for applications as human therapeutics. The company's lead drug candidate is the plant defensin, pezadeftide, which is in phase IIb clinical trials for the treatment of fungal toenail infections in Australia and New Zealand. Hexima Limited was incorporated in 1997 and is based in Preston, Australia.
Buy
Sell